Wikipedia:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Nicergoline: Difference between pages

{{Short description|Chemical compound}}

{{Use dmy dates|date=March 2024}}

{{Infobox drug

| Verifiedfields = changed

| verifiedrevid = 462260029

| IUPAC_name = [(6''aR'',9''R'',10''aS'')-10''a''-methoxy-4,7-dimethyl-6''a'',8,9,10-tetrahydro-6''H''-indolo[4,3-fg]quinolin-9-yl]methyl 5-bromopyridine-3-carboxylate

| image = Nicergoline Structure V.1.svg

| alt =

| tradename = Sermion

| routes_of_administration = [[Oral administration|By mouth]], [[intramuscular injection|intramuscular]], [[intravenous therapy|intravenous]]

| ATC_prefix = C04

| ATC_suffix = AE02

| ATC_supplemental =

| legal_status =

| legal_EU = Rx-only

| legal_EU_comment = <ref>https://www.ema.europa.eu/documents/psusa/nicergoline-list-nationally-authorised-medicinal-products-psusa/00002150/202005_en.pdf {{Bare URL PDF|date=March 2022}}</ref>

| metabolism = Extensive [[First-pass metabolism]]

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1372950

| synonyms = [(8β)-10-Methoxy-1,6-dimethylergolin-8-yl]methyl 5-bromopyridine-3-carboxylate

| C=24 | H=26 | Br=1 | N=3 | O=3

| SMILES = Brc1cc(cnc1)C(=O)OC[C@@H]3C[C@]4(OC)c5cccc2c5c(cn2C)C[C@H]4N(C3)C

'''Nicergoline''', sold under the brand name '''Sermion''' among others, is an [[ergot]] [[chemical derivative|derivative]] used to treat [[dementia|senile dementia]] and other disorders with [[blood vessel|vascular]] origins. Internationally it has been used for [[frontotemporal dementia]] as well as early onset in [[Lewy body dementia]] and [[Parkinson's dementia]]. It decreases [[vascular resistance]] and increases arterial blood flow in the brain, improving the utilization of oxygen and glucose by brain cells. It has similar vasoactive properties in other areas of the body, particularly the lungs. Unlike many other [[ergoline]]s, such as [[ergotamine]], nicergoline is not associated with [[cardiac fibrosis]].<ref name="ncbi.nlm.nih.gov">{{cite journal | vauthors = Zajdel P, Bednarski M, Sapa J, Nowak G | title = Ergotamine and nicergoline - facts and myths | journal = Pharmacological Reports | volume = 67 | issue = 2 | pages = 360–363 | date = April 2015 | pmid = 25712664 | doi = 10.1016/j.pharep.2014.10.010 | s2cid = 22768662 }}</ref>

It is used for vascular disorders such as cerebral [[thrombus|thrombosis]] and [[atherosclerosis]], arterial blockages in the limbs, [[Raynaud's disease]], vascular [[migraine]]s, and [[retinopathy]].

Nicergoline has been registered in over fifty countries and has been used for more than three decades for the treatment of cognitive, affective, and behavioral disorders of older people.<ref>{{cite journal | vauthors = Fioravanti M, Flicker L | title = Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment | journal = The Cochrane Database of Systematic Reviews | volume = 2001 | issue = 4 | pages = CD003159 | year = 2001 | pmid = 11687175 | pmc = 7025776 | doi = 10.1002/14651858.CD003159 }}</ref>

==Medical uses==

Nicergoline is used in the following cases:

* Acute and chronic cerebral metabolic-vascular disorders (cerebral arteriosclerosis, [[thrombosis]] and [[cerebral embolism]], transitory cerebral ischaemia). Acute and chronic peripheral metabolic-vascular disorders (organic and functional arteriopathies of the limbs), [[Raynaud's disease]] and other syndromes caused by altered peripheral irrigation.

* Migraines of vascular origin

* Coadjutant therapy in clinical situations accompanied by platelet hyper-aggregability, arterial tension.

* Corio-retinal vascular disorders: diabetic retinopathy, [[macular degeneration]] and retinal angiosclerosis

* Oto-vestibular problems of a vascular nature: dizziness, auditory hallucinations, [[hypoacusis]].

Dosages for known conditions are usually administered at 5–10&nbsp;mg three times a day, however anti-aging preventative purposes may want to consider 5&nbsp;mg once or twice a day more adequate.<ref>Nicergoline drug insert, Pharmacia & Upjohn, October 2000</ref>

==Contraindications==

Persons suffering from acute bleeding, [[myocardial infarction]] (heart conditions), hypertension, [[bradycardia]] or using alpha or beta receptor agonists should consult with their physician before use.

Although toxicology studies have not shown nicergoline to have any [[teratogenic effect]], the use of this medicine during pregnancy should be limited to those cases where it is absolutely necessary.

On 28 June 2013, the [[European Medicines Agency]] recommended restricting the use of medicines containing ergot derivatives, including nicergoline. They stated that "these medicines should no longer be used to treat several conditions involving blood circulation problems or problems with memory and sensation, or to prevent migraine headaches, since the risks are greater than the benefits in these indications. This is based on a review of data showing an increased risk of fibrosis (formation of excess connective tissue that can damage organs and body structures) and ergotism (symptoms of ergot poisoning, such as spasms and obstructed blood circulation) with these medicines.<ref>{{citation |url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/06/news_detail_001832.jsp&mid=WC0b01ac058004d5c1b |author= European Medicines Agency |contribution=New restrictions on use of medicines containing ergot derivatives |title= Press Release |date=28 June 2013}}</ref> However, only a subset of [[ergolines]] are associated with fibrosis and evidence suggests that nicergoline does not carry the same fibrotic risk like other ergoline derivatives such as [[ergotamine]].<ref name="ncbi.nlm.nih.gov"/>

Nicergoline is considered unsafe in [[porphyria]].<ref name=Martindale>{{Cite book|editor=Sweetman SC |chapter=Supplementary drugs and other substances|title=Martindale: It should be considered as last option in temporal impediments and build up of Lewy Bodies and obstructions contributed to "dementia" The complete drug reference |edition=36th |year=2009 |pages=2352 |publisher=Pharmaceutical Press |location=London|isbn=978-0-85369-840-1|title-link=Martindale: The complete drug reference}}</ref>

==Side effects==

The side effects of nicergoline are usually limited to nausea, hot flushes, mild gastric upset, hypotension and dizziness.<ref name=Martindale/> At high drug dosages, bradycardia, increased appetite, agitation, diarrhea and perspiration were reported. Most of the available literature suggests that the side effects of nicergoline are mild and transient.<ref name="ncbi.nlm.nih.gov"/>

== Interactions ==

Nicergoline is known to enhance the cardiac depressive effects of [[propranolol]].<ref name=Martindale/> At high dosages, it is advisable to seek one's physician's guidance if combining with potent [[vasodilators]] such as [[bromocriptine]], ''[[Ginkgo biloba]]'', [[picamilon]], [[vinpocetine]] or [[xantinol nicotinate]].

==Pharmacology==

===Pharmacodynamics===

Nicergoline is an ergot alkaloid derivative that acts as a potent and selective [[α1A-adrenergic receptor|α_1A-adrenergic receptor]] [[receptor antagonist|antagonist]].<ref>{{cite journal | vauthors = Alvarez-Guerra M, Bertholom N, Garay RP | title = Selective blockade by nicergoline of vascular responses elicited by stimulation of alpha 1A-adrenoceptor subtype in the rat | journal = Fundamental & Clinical Pharmacology | volume = 13 | issue = 1 | pages = 50–58 | year = 1999 | pmid = 10027088 | doi = 10.1111/j.1472-8206.1999.tb00320.x | s2cid = 43871763 }}</ref> The [[IC50|IC₅₀]] of nicergoline ''[[in vitro]]'' has been reported to be 0.2&nbsp;nM.<ref>{{cite journal | vauthors = Moretti A, Carfagna N, Caccia C, Carpentieri M | title = Effect of ergolines on neurotransmitter systems in the rat brain | journal = Archives Internationales de Pharmacodynamie et de Therapie | volume = 294 | pages = 33–45 | year = 1988 | pmid = 2906797 }}</ref> The primary action of nicergoline is to increase arterial blood flow by vasodilation. Furthermore, it is known that nicergoline inhibits [[Platelet aggregation#Adhesion and aggregation|platelet aggregation]]. Studies have shown that nicergoline also increases [[nerve growth factor]] in the aged brain.<ref>{{cite journal | vauthors = Nishio T, Sunohara N, Furukawa S, Akiguchi I, Kudo Y | title = Repeated injections of nicergoline increase the nerve growth factor level in the aged rat brain | journal = Japanese Journal of Pharmacology | volume = 76 | issue = 3 | pages = 321–323 | date = March 1998 | pmid = 9593228 | doi = 10.1254/jjp.76.321 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Mizuno T, Kuno R, Nitta A, Nabeshima T, Zhang G, Kawanokuchi J, Wang J, Jin S, Takeuchi H, Suzumura A | display-authors = 6 | title = Protective effects of nicergoline against neuronal cell death induced by activated microglia and astrocytes | journal = Brain Research | volume = 1066 | issue = 1–2 | pages = 78–85 | date = December 2005 | pmid = 16325157 | doi = 10.1016/j.brainres.2005.10.050 | s2cid = 34963522 }}</ref> In addition to the α_1A-adrenergic receptor, nicergoline is an antagonist of the [[serotonin]] [[5-HT1A receptor|5-HT_1A receptor]] (IC₅₀ = 6&nbsp;nM) and shows moderate [[affinity (pharmacology)|affinity]] for serotonin [[5-HT2 receptor|5-HT₂]] and [[α2-adrenergic receptor|α₂-adrenergic receptor]]s and low affinity for the [[dopamine]] [[D1 receptor|D₁]] and [[D2 receptor|D₂]] and [[muscarinic acetylcholine receptor|muscarinic acetylcholine]] [[muscarinic acetylcholine receptor M1|M₁]] and [[muscarinic acetylcholine receptor M2|M₂ receptor]]s.<ref name="ncbi.nlm.nih.gov"/> The major [[metabolite]]s of nicergoline, MMDL and MDL, show low or no affinity for [[adrenergic receptor|adrenergic]], [[serotonin receptor|serotonin]], [[dopamine receptor|dopamine]], or [[acetylcholine receptor]]s.<ref name="ncbi.nlm.nih.gov"/>

==Society and culture==

===Generic names===

''Nicergoline'' is the [[generic term|generic name]] of the drug and its {{Abbrlink|INN|International Nonproprietary Name}}, {{Abbrlink|USAN|United States Adopted Name}}, {{Abbrlink|BAN|British Approved Name}}, and {{Abbrlink|DCF|Dénomination Commune Française}}.<ref name="Elks2014">{{cite book|author=J. Elks|title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA864|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=864–}}</ref><ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA727|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=727–}}</ref>

== References ==

{{Reflist}}

{{Peripheral vasodilators}}

{{Navboxes

| title = [[Pharmacodynamics]]

| titlestyle = background:#ccccff

| list1 =

{{Adrenergic receptor modulators}}

{{Dopamine receptor modulators}}

{{Muscarinic acetylcholine receptor modulators}}

{{Serotonin receptor modulators}}

}}

{{Ergolines}}

{{Portal bar | Medicine}}

[[Category:5-HT1A antagonists]]

[[Category:Alpha-1 blockers]]

[[Category:Antidementia agents]]

[[Category:Bromoarenes]]

[[Category:Ethers]]

[[Category:Ergolines]]

[[Category:Nicotinate esters]]